The MIT cell therapy spinout priced its shares at the bottom of their range to raise $70.6m, following some $166m in venture funding.
SQZ Biotechnologies, a US-based cellular medicine developer based on research conducted at Massachusetts Institute of Technology (MIT), has floated in a $70.6m initial public offering.
The offering consisted of just over 4.4 million shares issued on the New York Stock Exchange (NYSE) and priced at $16.00 each at the foot of the IPO’s $16 to $18 range.
The company went public last Friday and its shares closed at $14.50 yesterday, valuing it at approximately $348m.
SQZ is developing…
